Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Abstract The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would substantial benefit controlling pandemic. Herein, we show MK-4482, an nucleoside analog, inhibits replication Syrian hamster model. inhibitory effect MK-4482 on is observed animals when drug either beginning 12 h before or infection a These data support potential utility to control humans as well treatment patients.